Zafirov, Dimche
Preferred name
Zafirov, Dimche
Official Name
Zafirov, Dimche
Main Affiliation
Email
dimce.zafirov@medf.ukim.edu.mk
26 results
Now showing 1 - 10 of 26
- Some of the metrics are blocked by yourconsent settings
Item type:Publication, A New Solid-Phase Extraction Method for Determination of Pantoprazole in Human Plasma Using High-Performance Liquid Chromatography(ID Design 2012/Scientific Foundation SPIROSKI, 2019-06-15); ; ; ; A new simple, selective and accurate high-performance liquid chromatographic (HPLC) method utilising solid-phase extraction for the determination of pantoprazole in human plasma samples has been developed. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Clearance of vancomycin calculated according to different formulas and their influence against different pharmacokinetic parameters(Medical Faculty, Ss. Cyril and Methodius University in Skopje, 2015); ; ; Zdravkovska, Milka - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparative, single-dose bioavailability study of two 500 mg clarithromycin tablet formulations in healthy volunteers under fasting condition(Macedonian Pharmaceutical Society, 2019); ; ; ; Clarithromycin is a semi-synthetic macrolide antibiotic, chemically 6-0- methylerythromycin, formulated as immediate-release tablets, extended-release tablets, and granules for oral suspension. The objective of this study was to evaluate and compare the relative bioavailability, and therefore the bioequivalence of Clarithromycin 500 mg test formulation versus a reference Klacid® forte 500 mg formulation, following a single dose administration under fasting conditions. The study was a single center, open, single dose, randomized, two-way crossover study in healthy male volunteers, with a wash-out period of one week between study periods. Twenty-four male healthy volunteers, aged 18-49 years were included into study. Blood samples for determination of clarithromycin and 14-OH clarithromycin concentrations were withdrawn at zero (pre-drug administration), 0.33, 0.66, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 and 36 hours post-drug administration. The determination of clarithromycin and 14-OH clarithromycin concentrations in plasma was performed using validated LC/MS/MS method and internal standardization after liquid/liquid extraction with methyl t-butyl ether. The test formulation of clarithromycin, dosed at 500 mg is bioequivalent for primary clarithromycin and 14-OH clarithromycin parameters (Cmax, AUC0-t and AUC0-∞) to the reference formulation after a single oral administration of 500 mg clarithromycin. Both medications were well tolerated with no serious adverse events. Thus, in view of the clinical use, both formulations are exchangeable without restrictions. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Comparative, Single-Dose, 2-Way Cross-Over Bioavailability Study of Two Olanzapine 10 Mg Tablet Formulations in Healthy Volunteers Under Fasting Conditions(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2022-07-13); ; ; ; Objectives: Olanzapine is an atypical antipsychotic that is approved across Europe, the USA, and in many other countries for oral treatment of schizophrenia and acute manic episodes in patients with bipolar disorder as well as for maintenance therapy to prevent recurrence in responders. The objective of the present study was to compare the pharmacokinetics of two 10 mg tablet formulations of Olanzapine following a single oral dose in healthy volunteers under fasting conditions, as per the European Medicine Agency (EMA) guidelines to grant marketing authorization. Methods: This study was a randomized, open-label, two-treatment, two-period, two-sequences, single-dose, cross-over design with a washout period of 14 days. Both the test and the reference products were administered as 10 mg tablets with 240 mL of water after an overnight fast in each study period. A total of twenty blood samples were collected before dosing and within 144 hours after drug administration. Adverse events were monitored, recorded, and evaluated by investigators throughout the study. Results: Of the 24 healthy adult male subjects enrolled, all of them completed both study periods. The geometric mean ratio 90% confidence intervals (CI) for fasting Cmax, AUC0-t, and AUC0-infinity were 94.83-113.71%, 95.04-105.69% and 95.94-107.00%, respectively. The 90% CI for the ratios of the three primary pharmacokinetic parameters (using log-transformed data) were within the range of 80-125%, meeting the regulatory criteria for bioequivalence. Conclusions: The generic Olanzapine was bioequivalent to the reference formulation. It was well tolerated and provides an acceptable alternative to the reference drug. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Protective Effects of At1-Receptor Blocker and Ca Antagonist Combination on Renal Function in Salt Loaded Spontaneously Hypertensive Rats/ Протективни Ефекти На Комбинацијата На Ат1 Рецепторен Блокатор И Калциум Антагонист Врз Реналната Функција Кај Спонтано Хипертензивни Стаорци Оптоварени Со Сол(Macedonian Academy of Sciences and Arts/Walter de Gruyter GmbH, 2015-05-01); ; ; ; Salt sensitive hypertension is known to be a contributing factor for the progression of kidney disease. This study was undertaken to investigate the role of excessive dietary salt on renal function and to evaluate the effect of valsartan and amlodipin given as a combination therapy on blood pressure and parameters specific to the renal function in salt loaded SHR rats. 48 male SHR rats at age of 20 weeks and body weight ranging between 270-350 g were used. SHR rats were divided into 3 groups: control group of rats -SHRC (n = 16) given tab water ad libitum and two salt treated groups in which tab water was replaced with a solution of NaCl (1%) from age of 8 weeks given ad libitum: SHRVAL+AMLO group (n = 16) where investigated drugs were administered at a dose of 10 mg/kg/ b.w. (valsartan) and 5 mg/kg/ b.w. (amlodipin) by gavage and SHR NaCl group (n = 16) that received saline in the same volume and the same time intervals as the SHRVAL+AMLO group. For a period of 12 weeks we have investigated the effect of the VAL+AMLO drug combination on systolic blood pressure (SBP), body weight and renal function tests. Salt loading with 1% solution in the SHR NaCl group has lead to significant increase of blood pressure, proteinuria and decrease in creatinine clearance. Combined treatment with АТ1-receptor blocker and calcium antagonist has managed to control blood pressure and ameliorated renal damage.</jats:p> - Some of the metrics are blocked by yourconsent settings
Item type:Publication, DIFFERENTIAL EFFECTS OF PEROXISOME PROLIFERATORACTIVATOR RECEPTOR (PPAR) ALPHA AND GAMMA AGONISTS ON BODY WEIGHT AND ADIPOSE DEPOTS IN FRUCTOSE FED WISTAR RATS(Macedonian Association of Anatomists, 2018); ; ; ; The aim of this study was to investigate the effect of fenofibrate (PPARalpha agonist) and rosiglitazone (PPAR-gamma agonist) on body weight and adipose depots in an experimental model of the metabolic syndrome. Metabolic syndrome was induced in 48 male Wistar rats by adding a fructose in drinking water (10% solution) for 12 weeks. During the last 4 weeks, 16 rats were treated with fenofibrate (100 mg/kg/day), 16 rats were treated with rosiglitazone (5 mg/kg/day) by intragastric tube, while the remaining 16 did not receive any medication (fructose group). Another control group of 16 rats consumed standard rat chow and water for 12 weeks. Chronic fructose administration for 12 weeks significantly increased the body weight (p<0.05), as well as the weight of the measured fat pads: perirenal (p<0.001) and epididymal (p<0.001) as representatives of the visceral adipose depots and the inguinal pads (p<0.05) as a representative of the subcutaneous adipose depots compared to the control group. This was accompanied with a decrease of the subcutaneous/visceral fat ratio. Treatment with fenofibrate over the final 4 weeks significantly decreased the body weight (p<0.001) and the weight of the epididymal, perirenal and inguinal fat pads (p<0.001 for all parameters), without changes of the subcutaneous/visceral fat ratio. On the other hand, rosiglitazone promoted weight gain. Treatment with this PPAR-gamma agonist significantly decreased the weight of the epididymal (p<0.01) and perirenal (p<0.05) pads, but increased the weight of the inguinal fat pads (p<0.001) compared to the fructose group, which led to an increase of the subcutaneous/visceral fat ratio. This study indicates that treatment with the PPAR-alpha agonist fenofibrate decreases body weight and reduces the fat depots, whereas PPAR-gamma agonist promotes weight gain and a body fat redistribution from visceral towards subcutaneous depots in an animal nutritive model of the metabolic syndrome - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Effects of Dual RAAS Blockade with Candesartan and Perindopril on Functional Renal Tests in Streptozotocin Induced Diabetic Nephropathy(Scientific Foundation SPIROSKI, 2013-09-15); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, EFFECTS OF VALSARTAN AND AMLODIPINE ON PROINFLAMMATORY CYTOKINES SERUM CONCENTRATIONS IN SALT LOADED SPONTANEOUSLY HYPERTENSIVE RATS(Japanese Pharmacological Society, 2018); ; ; ; - Some of the metrics are blocked by yourconsent settings
Item type:Publication, RELATION OF ENDOMETRIAL PATHOLOGICAL CHANGES WITH ENDOCRINE DISORDERS AND METABOLIC SYNDROME(Macedonian Association of Anatomists, 2021); ; ; ; Endometrial hyperplasia (EH) is an abnormal proliferation of endometrial glands and stroma and is associated with an increased risk of endometrial cancer (EC). Risk factors such as obesity, chronic anovulation, late menopause, hypertension, and diabetes lead to an increased risk of EH and EC. Aim: to determine the association of pathological changes in the endometrium with endocrine disorders and metabolic syndrome in women in peri and postmenopause. This study including a total of 139 patients in peri and postmenopause. The examined group consisted of 104 women with fractional explorative curettage due to a medical indication and was divided into two subgroups: peri and postmenopausal. The control group included 35 healthy women. Anamnestic data, body weight, height, blood pressure measurement, were taken from all patients, and the following laboratory parameters were determined: glucose, TSH, thyroxine, glycosylated hemoglobin (HbA1c), and Vitamin D . The presence of metabolic syndrome (MetS) according to its diagnostic criteria was also determined. In our study, significance was found in the comparison of the examined and the control group (p = 0.0001) in addition to the significantly higher BMI in the examined group. The comparison also indicated the existence of a significant difference in the level of glycemia in addition to a significantly higher level in the examined group (p = 0.0001). The statistical analysis did not indicate a significant difference between the two subgroups of the examined group, nor between the examined and the control group in terms of TSH, thyroxine and HbA1c levels. The value of vit. D was significantly higher in the control than in the study group (p = 0.0001). The analysis showed that patients with fractional explorative curettage had 4.982 times [OR = 4.982 (2.06–12.02) 99% CI] significantly more often MetS compared to women in the control group. Patients in the examined group had a significantly higher BMI, glycemia, and more frequent presence of MetS than those in the control group. - Some of the metrics are blocked by yourconsent settings
Item type:Publication, Cardiovascular effects of valsartan and amlodipine in salt-loaded spontaneously hypertensive rats(International Journal of Recent Research in Arts and Sciences, 2022-10); ; ; Bogoeva Kostovska, KsenijaSalt sensitivity defined as increase in blood pressure in response to high dietary salt intake, is an independent risk factor for cardiovascular disease and mortality [1]. Even in the absence of prominent elevations of blood pressure after salt-loading, salt sensitivity may be revealed by structural and functional injury to target organs such as vasculature, heart and kidneys [2-4]. Available data strongly suggest that salt overload exerts these adverse effects through pressure independent mechanisms [5, 6]. Moreover, recent results also suggest that the renin– angiotensin system (RAS) is involved in mediating the adverse effects of salt, since RAS blockade prevented or ameliorated salt-induced cardiovascular and renal injury [5, 7]. Treatment strategies give advantage to hypertension therapies that can provide benefits beyond blood pressure lowering. Angiotensin receptor blockers (ARBs) are often supplemented with calcium channel blockers (CCBs) for treatment of hypertension [8]. Valsartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively blocking the binding of angiotensin II to the AT1 receptor in the vascular smooth muscle. Amlodipine inhibits calcium ion influx across cell membranes, with a greater effect on vascular smooth muscle cells. This causes vasodilation and a reduction in peripheral vascular resistance, thus lowering blood pressure. The objective of this study was to evaluate protective effects of 12-week treatment with valsartan and amlodipine given as monotherapy and as a combination on the heart and large blood vessels histopathology in salt loaded SHR rats.
- «
- 1 (current)
- 2
- 3
- »